• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

早期进展的成本：表皮生长因子受体突变型转移性非小细胞肺癌患者。

Cost of early progression: patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer.

机构信息

Merative, Ann Arbor, MI 48103, USA.

Daiichi Sankyo, Basking Ridge, NJ 07920, USA.

出版信息

Future Oncol. 2024;20(24):1753-1764. doi: 10.1080/14796694.2024.2370186. Epub 2024 Jul 16.

DOI:10.1080/14796694.2024.2370186
PMID:39011928
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11486167/
Abstract

Compare healthcare costs for patients with epidermal growth factor receptor mutated (EGFRm) metastatic non-small-cell lung cancer (mNSCLC) with and without progression and estimate costs of progression. Retrospective claims analysis (2015-2020) from adults with EGFRm mNSCLC initiating EGFR tyrosine kinase inhibitors. Adjusted costs for 12 months were compared (with vs without progression) and cumulative costs for early versus late progression were predicted over 36 months. A total of 228 patients with EGFRm mNSCLC were included. Patients with progression within 12 months incurred significantly higher total costs despite lower treatment costs (vs without progression). Medical costs were significantly higher among early versus late progressors. These data may aid providers aiming to administer quality care in a cost-efficient way.

摘要

比较表皮生长因子受体突变（EGFRm）转移性非小细胞肺癌（mNSCLC）患者有和无进展的医疗费用，并估计进展的费用。对 2015-2020 年开始使用表皮生长因子受体酪氨酸激酶抑制剂的 EGFRm mNSCLC 成年患者进行回顾性索赔分析。比较了 12 个月的调整后费用（有进展与无进展），并预测了 36 个月内早期与晚期进展的累积费用。共纳入 228 例 EGFRm mNSCLC 患者。尽管治疗费用较低，但在 12 个月内进展的患者总费用明显更高（与无进展相比）。早期进展者的医疗费用明显高于晚期进展者。这些数据可能有助于旨在以具有成本效益的方式提供优质护理的提供者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/9f69d45362a1/IFON_A_2370186_F0007_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/3225abe4845b/IFON_A_2370186_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/c0c76e3fd6c3/IFON_A_2370186_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/43bef7b30743/IFON_A_2370186_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/c6408985b2f1/IFON_A_2370186_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/79051374f237/IFON_A_2370186_F0005_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/77a732455e18/IFON_A_2370186_F0006_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/9f69d45362a1/IFON_A_2370186_F0007_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/3225abe4845b/IFON_A_2370186_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/c0c76e3fd6c3/IFON_A_2370186_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/43bef7b30743/IFON_A_2370186_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/c6408985b2f1/IFON_A_2370186_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/79051374f237/IFON_A_2370186_F0005_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/77a732455e18/IFON_A_2370186_F0006_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/651b/11486167/9f69d45362a1/IFON_A_2370186_F0007_C.jpg

相似文献

1
Cost of early progression: patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer.早期进展的成本：表皮生长因子受体突变型转移性非小细胞肺癌患者。
Future Oncol. 2024;20(24):1753-1764. doi: 10.1080/14796694.2024.2370186. Epub 2024 Jul 16.
2
Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by mutation type.基于突变类型的晚期或转移性非小细胞肺癌患者的真实世界治疗模式、医疗资源利用和成本。
J Med Econ. 2024 Jan-Dec;27(1):219-229. doi: 10.1080/13696998.2024.2309838. Epub 2024 Feb 13.
3
Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan.阿法替尼用于美国医保计划中表皮生长因子受体 exon19 缺失或 exon21 替换突变的转移性非小细胞肺癌一线治疗的预算影响分析。
J Manag Care Spec Pharm. 2018 Jun;24(6):544-553. doi: 10.18553/jmcp.2018.24.6.544.
4
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).优化表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）中酪氨酸激酶抑制剂（TKI）的治疗顺序。
Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.
5
Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting.在一线治疗中，接受表皮生长因子受体酪氨酸激酶抑制剂治疗与接受免疫治疗或化疗治疗的表皮生长因子受体突变型非小细胞肺癌患者的真实世界结局。
Cancer Med. 2023 Jun;12(12):13415-13425. doi: 10.1002/cam4.6052. Epub 2023 Jun 12.
6
The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (m NSCLC) in Sweden.达可替尼在瑞典用于治疗表皮生长因子受体突变阳性的晚期/转移性非小细胞肺癌（m NSCLC）一线治疗的成本效益。
J Med Econ. 2021 Jan-Dec;24(1):447-457. doi: 10.1080/13696998.2021.1901722.
7
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.具有罕见或复杂表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者的临床特征及治疗结果
Oncotarget. 2017 May 16;8(20):32626-32638. doi: 10.18632/oncotarget.15945.
8
Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.晚期非小细胞肺癌患者的医疗费用及靶向治疗期间的疾病进展：一项真实世界观察性研究。
J Med Econ. 2018 Feb;21(2):192-200. doi: 10.1080/13696998.2017.1389744. Epub 2017 Oct 18.
9
Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.表皮生长因子突变检测的应用及其对非小细胞肺癌治疗模式的影响：一项国际观察性研究
Lung Cancer. 2023 Jan;175:47-56. doi: 10.1016/j.lungcan.2022.11.009. Epub 2022 Nov 17.
10
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.非小细胞肺癌脑转移的治疗。
Int J Mol Sci. 2021 Jan 8;22(2):593. doi: 10.3390/ijms22020593.

本文引用的文献

1
A New Approach to Cancer Bundled Payments in Medicare-The Enhancing Oncology Model.医疗保险中癌症捆绑支付的新方法——强化肿瘤学模式。
JAMA Health Forum. 2023 Jan 6;4(1):e224904. doi: 10.1001/jamahealthforum.2022.4904.
2
Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis.携带常见和罕见表皮生长因子受体（EGFR）突变的非小细胞肺癌的治疗策略：基于外显子分类的药物敏感性及结构-功能分析
Cancers (Basel). 2022 May 20;14(10):2519. doi: 10.3390/cancers14102519.
3
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
奥希替尼对比铂类培美曲塞用于既往 EGFR 酪氨酸激酶抑制剂治疗进展的 EGFR T790M 阳性晚期 NSCLC 患者：AURA3 总生存分析。
Ann Oncol. 2020 Nov;31(11):1536-1544. doi: 10.1016/j.annonc.2020.08.2100. Epub 2020 Aug 27.
4
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced -Mutated Non-small Cell Lung Cancer: A Meta-Analysis.表皮生长因子受体（EGFR）抑制剂联合抗血管生成药物作为晚期EGFR突变非小细胞肺癌患者一线治疗的疗效和安全性：一项荟萃分析
Front Oncol. 2020 Jun 25;10:904. doi: 10.3389/fonc.2020.00904. eCollection 2020.
5
Medical Care Costs Associated with Cancer Survivorship in the United States.美国癌症生存者相关的医疗保健费用。
Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7):1304-1312. doi: 10.1158/1055-9965.EPI-19-1534. Epub 2020 Jun 10.
6
Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.转移性乳腺癌、肺癌和结直肠癌患者的疾病进展成本。
Oncologist. 2019 Sep;24(9):1209-1218. doi: 10.1634/theoncologist.2018-0018. Epub 2019 Feb 22.
7
Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common mutations.具有常见突变的肺腺癌患者中一线表皮生长因子受体酪氨酸激酶抑制剂应答者和非应答者的生存相关因素
Mol Clin Oncol. 2018 Mar;8(3):421-428. doi: 10.3892/mco.2018.1550. Epub 2018 Jan 10.
8
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.晚期非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂靶向治疗获得性耐药的管理。
Mol Cancer. 2018 Feb 19;17(1):38. doi: 10.1186/s12943-018-0777-1.
9
Cancer statistics, 2018.癌症统计数据，2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
10
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.